Dexcom’s “Smart Basal” has received FDA clearance for people with type 2 diabetes using long-acting insulin. The feature will ...

Dexcom (NSDQ:DXCM) announced today that it plans to launch its G7 15 Day continuous glucose monitor (CGM) in the U.S. next ...

Dexcom ($DXCM) unveiled new data-sharing capabilities for its cloud-based diabetes management platform, Clarity. Now, patients and physicians may easily share data ...

Mobile app allows patients to quickly access glucose data on their phone for diabetes management Dexcom, Inc. (NASDAQ:DXCM), a leader in continuous glucose monitoring ...

FDA clears Dexcom G7 15-Day CGM for adults, offering 15.5 days of wear and a MARD of 8.0% for improved diabetes management. New features include Apple Watch connectivity, medication logging, and ...

After months of international availability, the Dexcom G7 constant glucose monitor received its FDA clearance to distribute in the US. Ahead of the wide rollout, we got to go hands-on with a demo ...

SAN DIEGO--(BUSINESS WIRE)--DexCom, Inc. (NASDAQ: DXCM), the leader in continuous glucose monitoring (CGM) for people with diabetes, announced today that it incorporated Ambulatory Glucose Profile ...

Dexcom (NSDQ:DXCM) announced today that the FDA cleared its Smart Basal CGM-integrated basal insulin dosing optimizer.